Skip to main content
Log in

Hypercalcaemia

What Does it Signify?

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Hypercalcaemia can be caused by many disorders, but is most commonly due to primary hyperparathyroidism in outpatients, and to malignant disease in hospital inpatients. When mild (< 3 mmol/L) it does not cause symptoms, but can have long term effects such as renal calculi. It is important that the aetiology of the hypercalcaemia be established, as it can reflect serious disease. In most patients the correct diagnosis can be suspected from clinical history and examination, and confirmed by laboratory tests and x-rays. The most difficult diagnostic problem is the patient with negative clinical findings,mild hypercalcaemia and mild renal impairment, when the parathyroid hormone level is normal or slightly elevated.

When hypercalcaemia is severe (> 3.5 mmol/L), it can cause vomiting, polyuria, dehydration and renal impairment, and is then an important therapeutic problem. Therapy includes treatment of the cause, such as radiotherapy for malignant disease or surgery for primary hyperparathyroidism. In addition, it is usually necessary to treat the hypercalcaemia itself, and the initial step is always rehydration. If the plasma calcium concentration remains high, drug treatment must be added, the most effective and reliable agent being intravenous mithramycin. Aminohydroxypropylidene diphosphonate (APD), though less studied, may be equally useful in this situation. Glucocorticoids are not always effective, and phosphate may cause renal damage, particularly when given intravenously. For long term treatment of malignant hypercalcaemia, oral glucocorticoids and phosphate are often effective, and can be given in combination. When primary hyperparathyroidism cannot be corrected surgically, the hypercalcaemia (and hypercalciuria) are probably best treated with a low calcium diet and cellulose phosphate, a regimen also effective for the hypercalcaemia of sarcoidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Ananth, J. and Dubin, S.E.: Lithium and symptomatic hyperparathyroidism. Journal of the Royal Society of Medicine 76: 1026 (1983).

    PubMed  CAS  Google Scholar 

  • Arruda, J.A.L. and Kurtzman, N.A.: Hyperparathyroidism and metabolic acidosis. Nephron 26: 1 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Boyde, A.: Evidence against osteocytic osteolysis; in Jee and Parfitt (Eds) Bone Histomorphometry, p. 239 (SNPMD, Paris 1981).

    Google Scholar 

  • Boyle, I.T. and Fogelman, I.: Glucocorticoids and oestrogens in the management of hypercalcaemia. Metabolic Bone Disease and Related Research 2: 203 (1980).

    Article  Google Scholar 

  • Breukelen, F.J.M. et al.: Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-biphosphonate (APD). Lancet 1: 803 (1979).

    Article  PubMed  Google Scholar 

  • Broadus, A.E. et al.: Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. Journal of Clinical Investigation 60: 771 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Chakmakjian, Z.H. and Bethune, J.E.: Sodium sulphate treatment of hypercalcaemia. New England Journal of Medicine 275: 862 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Christensson, T. et al.: Prevalence of hypercalcaemia in a health screening in Stockholm. Acta Medica Scandinavica 200: 131 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Coe, F.C. and Favus, M.J.: Does mild asymptomatic primary hyperparathyroidism require surgery? New England Journal of Medicine 302: 224 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Coombes, R.C. et al.: Mithramycin therapy: An adjunct to conventional treatment of hypercalcaemia and bone metastases in breast cancer. Metabolic Bone Disease and Related Research 2: 199 (1980).

    Article  Google Scholar 

  • Drezner, M.K. and Lebovitz, H.E.: Primary hyperparathyroidism in paraneoplastic hypercalcaemia. Lancet 1: 1004 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Dudley, F.J. and Blackburn, C.R.B.: Extraskeletal calcification complicating oral neutral phosphate therapy. Lancet 2: 628 (1970).

    Article  PubMed  CAS  Google Scholar 

  • Evans, R.A. et al.: Histochemical identification of osteoclasts in undecalcified sections of human bone. Mineral and Electrolyte Metabolism 2: 179 (1979).

    CAS  Google Scholar 

  • Evans, R.A. et al.: Immobilisation hypercalcaemia. Mineral and Electrolyte Metabolism 1: 244 (1984).

    Google Scholar 

  • Heath, H. et al.: Primary hyperparathyroidism. New England Journal of Medicine 302: 189 (1980).

    Article  PubMed  Google Scholar 

  • Hosking, D.J.: Treatment of severe hypercalcaemia with calcitonin. Metabolic Bone Disease and Related Research 2: 207 (1980).

    Article  Google Scholar 

  • Jung, A.: Comparision of two parenteral disphosphonates in hypercalcaemia of malignancy. American Journal of Medicine 72: 221 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Knochel, J.P.: Serum calcium derangements in rhabdomyolysis. New England Journal of Medicine 305: 161 (1981).

    Article  PubMed  CAS  Google Scholar 

  • McDonnell, G.D. et al.: Quantitative bone histology in the hypercalcaemia of malignant disease. Journal of Clinical Endocrinology and Metabolism 55: 1066 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Mundy, G.R. et al.: Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England Journal of Medicine 291: 1041 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Parfitt, A.M.: The actions of parathyroid hormone on bone (Part 2). Metabolism 25: 909 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Payne, R.B.: Clinically significant effect of protein concentration on ion selective electrode measurements of ionised calcium. Annals of Clinical Biochemistry 19: 233 (1982).

    PubMed  CAS  Google Scholar 

  • Scholz, D.A. and Purneil, D.C.: Asymptomatic primary hyperparathyroidism. Proceedings of the Mayo Clinic 56: 473 (1981).

    CAS  Google Scholar 

  • Shackney, S. and Hasson, J.: Precipitous fall in serum calcium, hypotension and acute renal failure after intravenous phosphate therapy for hypercalcaemia. Annals of Internal Medicine 66: 906 (1967).

    PubMed  CAS  Google Scholar 

  • Skrabanek, P. et al.: Tumour hypercalcaemia and ‘ectopic hyperparathyroidism’. Medicine (Baltimore) 59: 262 (1980).

    CAS  Google Scholar 

  • Somerville, P.J. and Evans, R.A.: What is tertiary hyperparathyroidism? Australian and New Zealand Journal of Medicine 5: 551 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Suki, W.N.: Acute treatment of hypercalcaemia with frusemide. New England Journal of Medicine 283: 836 (1970).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evans, R.A. Hypercalcaemia. Drugs 31, 64–74 (1986). https://doi.org/10.2165/00003495-198631010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198631010-00005

Keywords

Navigation